Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner
| Autor: | P.J. van Santbrink, Mara J. Kröner, Hidde Douna, Paul H.A. Quax, G.H.M. van Puijvelde, Johan Kuiper, Ilze Bot, Frank H. Schaftenaar, Jacob Amersfoort |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Myeloid Cell Disease 030204 cardiovascular system & hematology Biology Lipocalin Monocytes Flow cytometry 03 medical and health sciences 0302 clinical medicine Immune system Lipocalin-2 medicine Necrotic core chemistry.chemical_classification medicine.diagnostic_test Atherosclerosis 030104 developmental biology medicine.anatomical_structure chemistry Cancer research Biomarker (medicine) Cardiology and Cardiovascular Medicine Glycoprotein MMP-9 |
| Zdroj: | Atherosclerosis, 275, 214-224 Atherosclerosis |
| Popis: | Lipocalin-2 (Lcn2) is a glycoprotein which can be secreted by immune cells. Several studies in humans have suggested Lcn2 can be used as a biomarker for the detection of unstable atherosclerotic lesions, partly as it is known to interact with MMP-9. mice to assess the functional role of Lcn2 in different stages of atherosclerosis. Atherosclerotic lesions were characterized through histological analysis and myeloid cell populations were examined using flow cytometry. mice. Altogether, these findings suggest that Lcn2 deficiency promotes lesion growth in earlier stages of the disease while it decreases MMP-9 activity and necrotic core size in advanced atherosclerosis. BACKGROUND AND AIMS METHODS RESULTS CONCLUSIONS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|